Short answer
If a company talks about its approved or investigational product on a podcast, the episode and every clip can count as promotion. FDA rules ban promoting investigational drugs as safe or effective and expect fair balance for approved ones. CatalystX Media supports medical, legal and regulatory review with transcripts and timestamped edit logs.
Key takeaways
- Clips and trailers are judged on their own, not as part of the full episode.
- A benefit claim in a clip without risk information can fail fair balance.
- Investigational products cannot be promoted as safe or effective.
- This page is general information, not regulatory advice.
Why does a clip need its own review?
Because a viewer sees the clip without the rest of the episode. A 40-second clip that keeps a benefit claim but drops the risk discussion that followed can read as unbalanced promotion. Review each clip and trailer as a standalone piece, and use verbatim lines so nothing is reworded.
What do FDA rules say about investigational products?
US regulations say a sponsor may not represent an investigational new drug as safe or effective for the purposes it is being studied for, or otherwise promote it. Scientific exchange is allowed, but the line is easy to cross in a relaxed conversation, so brief guests before recording.
See 21 CFR 312.7 and, for prescription drug advertising, 21 CFR 202.1.
How can a podcast make MLR review faster?
Give reviewers a transcript, a timestamped edit log and the clips as separate files with their own transcripts. Flag every claim, number and product mention. When reviewers ask for a change, apply it as a marked revision so they can confirm it without watching the whole episode again.
Sources
Published 22 November 2026 · Last updated 22 November 2026
CatalystX Media

